telitacicept Updated Nov 13
The next major catalyst is the topline readout from the global Phase 3 UPSTREAM MG trial in generalized myasthenia gravis, expected in the first half of 2027. Positive data would support US/EU regulatory filings and validate Vor Bio's strategy of replicating RemeGen's Chinese clinical success globally. Negative or mixed results would severely damage the thesis, as telitacicept is Vor Bio's lead asset. Also watch for enrollment completion updates from the UPSTREAM SjD Phase 3 trial in Sjogren's disease.
- Telitacicept has already demonstrated strong efficacy across multiple autoimmune indications in China, including NMPA approvals for SLE, IgA nephropathy, and Sjogren's disease, de-risking the mechanism.
- The global Phase 3 UPSTREAM MG trial is fully enrolled with topline results expected 1H 2027; positive data could unlock a multi-billion-dollar US/EU market opportunity.
- Vor Bio holds ~$491-514 million in cash (pro-forma), providing runway through early 2029 and fully funding the global Phase 3 program without near-term dilution risk.
- Telitacicept is not yet approved outside China; global regulatory path depends on replicating Chinese Phase 3 results in Vor Bio's own global trials, which carries execution risk.
- Vertex's povetacicept (a competing dual BAFF/APRIL inhibitor) has an upcoming FDA decision and could establish a competitive lead in the same mechanism class.
- Vor Bio's original oncology pipeline was deprioritized for this autoimmune pivot; investors are betting on a single drug class with no marketed products yet in ex-China markets.